Visual Universitätsmedizin Mainz

Reviews und Editorials

Peer reviewed and PubMed-cited


1. Felber J, Stallmach A, Schuppan D. [Comment]. Z Gastroenterol. 2015 Apr; 53(4):342-3.
 

2. Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis. 2015 May; 35(2):184-98.
 

3. Schuppan D, Zevallos V. Wheat amylase trypsin inhibitors as nutritional activators of innate immunity. Dig Dis. 2015; 33(2):260-3.
 

4. Kahaly GJ, Schuppan D. Celiac disease and endocrine autoimmunity. Dig Dis. 2015; 33(2):155-61.
 

5. Mulder CJ, Schuppan D. Small bowel: from sideline to center stage in gastroenterology. Dig Dis. 2015; 33(2):113-4.
 

6. Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to   treatment. J Hepatol. 2015 Apr; 62(1S):S15-S24.
 

7. Corley DA, Schuppan D. Food, the immune system, and the gastrointestinal tract. Gastroenterology. 2015 May; 148(6):1083-6.
 

8. Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JM, Hansen NU, Bay-Jensen AC, Bager CL, Krag A, Blanchard A, Krarup H, Leeming DJ, Schuppan D. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015 May 15; 308(10):G807-G830.
 

9. Stallmach A, Schuppan D. [Diagnostics and treatment of celiac disease]. Dtsch Med Wochenschr. 2015 Feb; 140(3):198. doi: 10.1055/s-0041-100132. Epub 2015.
 

10. J Torok N, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: SAummary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology. 2015 Jan 27. doi: 10.1002/hep.27720. [Epub ahead of print].
 

11. Fasano A, Sapone A, Zevallos V, Schuppan D. Nonceliac gluten sensitivity. Gastroenterology. 2015 May; 148(6):1195-204. doi: 10.1053/j.gastro.2014.12.049. Epub 2015 Jan 9. PubMed PMID: 25583468.
 

12. Fasano A, Sapone A, Zevallos V, Schuppan D. Non-celiac Gluten Sensitivity. Gastroenterology. 2015 Jan 9. pii: S0016-5085(15)00029-3. doi: 10.1053/j.gastro. 2014.12.049.
 

13. Felber J, Aust D, Baas S, Bischoff S, Bläker H, Daum S, Keller R, Koletzko S, Laass M, Nothacker M, Roeb E, Schuppan D, Stallmach A. [Results of a S2k-Consensus Conference of the German Society of Gastroenterolgy, Digestive- and Metabolic Diseases (DGVS) in conjunction with the German Coeliac Society (DZG)regarding coeliac disease, wheat allergy and wheat sensitivity]. Z Gastroenterol 2014;52:711-43.
 

14. Zhang L, Schuppan D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: Hope and hype. J Hepatol 2014;61:166-8.
 

15. Schuppan D, Zimmer KP. The diagnosis and treatment of celiac disease. Dtsch Arztebl Int. 2013;110:835-46.
 

16. Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W, Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013;5:3839-53.
 

17. Lukacs-Kornek V, Schuppan D. Dendritic cells in liver injury and fibrosis: shortcomings and promises. J Hepatol 2013;59:1124-6.
 

18. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013 Aug;28 Suppl 1:68-76.
 

19. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-901.
 

20. Olinga P, Schuppan D. Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol 2013;58:1252-3.
 

21. Bai JC, Fried M, Corazza GR, Schuppan D, Farthing M, Catassi C, Greco L, Cohen H, Ciacci C, Eliakim R, Fasano A, González A, Krabshuis JH, LeMair A. World gastroenterology organisation global guidelines on celiac disease. J Clin Gastroenterol 2013;47:121-6.
 

22. Weng SY, Schuppan D. AMPK regulates macrophage polarization in adipose tissue inflammation and NASH. J Hepatol 2013;58:619-21.
 

23. Zevallos VF, Schuppan D. Refractory coeliac disease: one step closer to the origin of aberrant lymphocytes. Gut 2013;62:485-6.
 

24. Berenguer M, Schuppan D. Progression of Liver Fibrosis in Post-Transplant Hepatitis C: Mechanisms, Assessment and Treatment. J Hepatol 2013;58:1028-41.
 

25. Mukherjee R, Kelly CP, Schuppan D. Nondietary therapies for celiac disease. Gastrointest Endosc Clin N Am 2012;22:811-31.
 

26. Kornek M, Schuppan D. Microparticles: Modulators and biomarkers of liver disease. J Hepatol 2012;57:1144-46.
 

27. Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol 2012;56 Suppl 1:S66-74.
 

28. Kim YO, Schuppan D. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. Am J Physiol Gastrointest Liver Physiol 2012;302:G759-61.
 

29. Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011;22:479-88.
 

30. Poelstra K, Schuppan D. Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol 2011;55:726-8.
 

31. Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol 2010 ;105:2520-4.
 

32. Malik R, Schuppan D. Serum fibrosis markers to predict clinical and histological progression in hepatitis C non-responders. Gut 2010;59:1312-3.
 

33. Popov Y, Schuppan D. Epithelial-to-mesenchymal transition in liver fibrosis: dead or alive? Gastroenterology 2010;139:722-5.
 

34. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 2010;30:795-808.
 

35. Robson SC, Schuppan D. Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J Hepatol 2010;52:941-3.
 

36. Popov Y, Schuppan D. CD8+ T cells drive adipose tissue inflammation-a novel clue for NASH pathogenesis? J Hepatol 2010;52:130-2.
 

37. Marietta E, Schuppan D, Murray JA. In vitro and in vivo models of celiac disease. Exp Opin Drug Discov 2009; 11:1113-1123.
 

38. Schuppan D, Junker Y, Barisani D. Celiac Disease: From Pathogenesis to novel therapies. Gastroenterology 2009;137:1912-33.
 

39. Popov Y, Schuppan D. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatology 2009;50:1294-1306.
 

40. Schuppan D, Popov Y. Rationale and targets for treatment of liver fibrosis. Gastroenterol Clin Biol 2009;33:959-67.
 

41. Elli L, Bergamini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009;51:541-50.
 

42. Hopfner M, Schuppan D, Scherubl H. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World J Gastroenterol 2008;14:7021-32.
 

43. Schuppan D, Afdhal NH. Lancet Seminars: Liver cirrhosis. Lancet 2008; 371:838-51.
 

44. Hopfner M, Schuppan D, Scherubl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World J Gastroenterol. 2008;14:2461-73.
 

45. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008:14:1-14.
 

46. Schuppan D, Kelly CP. Serological screening for celiac disease. Nat Clin Pract Gastroenterol 2008;5:70-71.
 

47. Dieterich W, Schuppan D. Is gliadin harmful from the first morsel? Dig Liver Dis 2007;39:917-21.
 

48. Schuppan D, Junker Y. Turning swords into plowshares: transglutaminase to detoxify gluten. Gastroenterology 2007;133:1025-8.
 

49. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007;39:293-304.
 

50. Schuppan D, Kelly CP, Krauss N. Monitoring non-responsive patients with celiac disease. Gastrointest Endosc Clin N Am 2006;16:593-603.
 

51. Stickel F, Schuppan D. Herbal hepatotoxicity. J Hepatol 2006;45:335-6.
 

52. Mueller S, Afdhal NH, Schuppan D. Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology 2006;130:2229-34.
 

53. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005;43:901-10.
 

54. Koning F, Schuppan D, Cerf-Bensussan N, Sollid LM. Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol 2005;19:373-87.
 

55. Schuppan D, Dennis MD, Kelly CP. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. Nutr Clin Care 2005;8:54-69.
 

56. Stolzel U, Teubner A, Ernstberger J, Habeck JO, Schuppan D. Isolated elevation of gGT: What should be the diagnostic approach? Dtsch. Med Wochenschr 2004;129 Suppl 2:S54-6.
 

57. Freitag T, Schuppan D (2004). Screening for coeliac disease antigen source and performance of the anti-tissue transglutaminase ELISA. Dig Liver Dis 2004;36:658-60.
 

58. Freitag T, Schulze-Koops H, Niedobitek G, Melino G, Schuppan D. The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease. Autoimmun Rev 2004;3:13-20.
 

59. Schuppan D, Freitag T. Fistulising Crohn's disease: MMPs gone awry. Gut 2004;53:622-4.
 

60. Stickel F, Hoehn B, Schuppan D, Seitz HK. Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003;18:357-373
 

61. Dieterich W, Esslinger B, Schuppan D. Pathomechanisms in celiac disease. Int Arch Allergy Immunol 2003;132:98-108.
 

62. Schuppan D, Esslinger B. Celiac disease: diagnosis, pathogenesis and treatment. D Med Wschr 2003;128 Suppl. 1:1-3.
 

63. Schuppan D, Ocker M. Integrin-mediated control of cell growth. Hepatology. 2003; 38: 289-91.
 

64. Schuppan D, Esslinger B, Dieterich W. Celiac disease and innate immunity: friend or foe? Lancet 2003;362:3-4.
 

65. Stickel F, Seitz HK, Hahn EG, Schuppan D. Alcoholic liver disease. Z Gastroenterol 2003;41:333-42.
 

66. 55) Schuppan D, Dieterich W. A molecular warhead and its target. Tissue transglutaminase and celiac sprue. Chem Biol 2003;10:199-201.
 

67. 56) Schuppan D, Krebs A, Bauer M, Y. Popov, Hahn EG. Hepatitis C and fibrosis progression. Cell Death Diff 2003;10 Suppl 1:59-67.
 

68. Schuppan D, Hahn EG. Gluten and the gut: lessons for immune regulation. Science 2002;297:2218-20.
 

69. Schuppan D, Popov Y. Hepatic fibrosis: from bench to bedside. J Gastroenterol Hepatol 2002;17 Suppl 3:300-5.
 

70. Stickel F, Brinkhaus B, Krahmer N, Seitz HK, Hahn EG, Schuppan D. Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology 2002;49:1102-8.
 

71. Schuppan D, Ciccocioppo R. Coeliac disease and secondary autoimmunity. Dig Liver Dis 2002;34:13-5.
 

72. Stickel F, Schuppan D, Hahn EG, Seitz HK. Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut 2002;51:132-9
 

73. Schuppan D, Bauer M. TGFbeta1 in liver fibrosis: time to change paradigms? FEBS Lett 2001;502:1-3.
 

74. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Sem Liver Dis 2001;21:351-72,
 

75. Schuppan D, Hahn EG. IgA anti tissue transglutaminase: setting the stage for celiac disease screening. Eur J Gastroenterol Hepatol 2001;13:635-7.
 

76. Stickel F, Schuppan D, Hahn EG. Hepatotoxicity of herbal remedies. Z Gastroenterol 2001; 39:225-37.
 

77. Schuppan D, Hahn EG. Clinical studies with silymarin: fibrosis progression is the end point. Hepatology 2001; 33: 483-4.
 

78. Catassi C, Cellier C, Cerf-Bensussan N, Ciclitira PJ, Collin P, Corazza GR, Dickey W, Fasano A, Holmes GKT, Klincewicz P, Mearin ML, Mulder CJJ, Murray JA, Pena AS, Schuppan D, Sollid LM, Uil JJ, Wahab PJ, Walker-Smith JA, Watson P, Van Belzen M, Von Blomberg BME, Bouquet J, Bijleveldt CMA, Crusius JBA, Douwes AC, George EK, Hamer RJ, Janssen FW, Meyer JWR, Sinaasappel M, Rostami K, Taminiau JAJM, Vader LW, Wijmenga C. When is a coeliac a coeliac? Report of a working group of the United European Gastroenterology Week in Amsterdam, 2001. Eur J Gastroenterol Hepatol 2001;13:1123-1128.
 

79. Schuppan D, Hahn EG. Celiac disease, an autoimmune disorder linked to type I diabetes. J Ped Endocrinol Metab 2001;14 Suppl 1:597-605.
 

80. Schuppan D, Hahn EG. Interleukin-10: The magic bullet for liver fibrosis? Gastroenterology 2000;119:1412-4.
 

81. Schuppan D. Liver fibrosis: Pathogenesis, prevention and treatment. Rev Gastroenterol Peru 2000;20: 164-168.
 

82. Schuppan D. Novel concepts of coeliac disease pathogenesis. Gastroenterology 2000;119:234-42.
 

83. Dieterich W, Storch W, Schuppan D. Serum antibodies in celiac disease. Clin Lab 2000;46:361-4.
 

84. Schuppan D, Hahn EG. MMPs in the gut: inflammation hits the matrix. Gut 2000;47:12-4.
 

85. Schuppan D, Koda M, Bauer M, Hahn EG. Fibrosis of the liver, pancreas and intestine: common mechanisms and clear targets? Acta Gastroenterol Belg 2000;63:366-70.
 

86. Stoelzel U, Tannapfel A, Wittekind C, Hamm B, Schuppan D. Indications for liver biopsies in hepatic cancers. D Med Wschr 2000;125:1041-4.
 

87. Schuppan D, Jax C, Hahn EG. Serum markers of liver fibrosis. D. Med. Wschr. 1999; 124: 1213-8.
 

88. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases. A therapeutic challenge for the new millenium. Hepatology 1999;30:1099-1004.
 

89. Schuppan D, Cho JJ, Jia JD, Hahn EG. Interplay of matrix and myofibroblasts during hepatic fibrogenesis. Curr Top Pathol 1999;93:205-18.
 

90. Schuppan D, Dieterich W, Riecken EO. Exposing gliadin as a tasty food for lymphocytes. Nat Med 1998;4:666-7.
 

91. Riecken EO, Daum S, Schulzke JD, Dieterich W, Schuppan D. Celiac sprue. Tissue transglutaminase as autoantigen – novel aspects in diagnosis and etiopathogenesis. D Med Wschr 1998;123:1454-60.
 

92. Schuppan D, Strobel D, Hahn EG. Hepatic fibrosis - therapeutic strategies. Digestion 1998;59:385-90.
 

93. Schuppan D. Chronic hepatitis: Antifibrotic therapies. Z Allg Med 1995;71:1153-7.
 

94. Schuppan D. Chronic hepatitis: Problems of antifibrotic therapy. Z Allg Med. 1995;71:1144-50.
 

95. Schuppan D, Atkinson J, Riecken EO. Alcohol and liver fibrosis: Pathobiochemistry and treatment. Z Gastroenterol 1995;30:546-50.
 

96. Herbst H, Schuppan D, Milani S. Fibrogenesis and fibrolysis in liver. Verh Dtsch Ges Path. 1995;79:15-27.
 

97. Schuppan D, Stölzel U, Oesterling C, Somasundaram R. Serum markers for liver fibrosis. J Hepatol 1995;22 Suppl 2:82-8.
 

98. Milani S, Herbst H, Schuppan D, Grappone C, Heinrichs OE. Cellular sources of extracellular matrix proteins. Studies of gene expression by in situ hybridization. J Hepatol 1995;22 Suppl 2:71-6.
 

99. Schuppan D, Rühl M. Matrix in signal transduction and growth factor modulation. Braz J Med Biol Res 1994;27:2125-42.
 

100.Schuppan D, Somasundaram R, Dieterich W, Ehnis T, Bauer M. The extracellular matrix in cellular differentiation and proliferation. Ann NY Acad Sci 1994;733:87-102.
 

101.Schuppan D. Vitamin A and liver fibrosis-cure or villain? J Lab Clin Med 1992;119:590-1.
 

102.Herbst H, Milani S, Heinrichs O, Schuppan D. Pathomorphology of acute and chronic stages of CCl4–induced liver fibrosis: Immunhistochemical and in situ hybridization studies. Z Gastroenterol 1992;30 Suppl 3:21-8.
 

103.Schuppan D. Connective tissue polypeptides in serum: Novel parameters of matrix synthesis and degradation in hepatic fibrosis. Z Gastroenterol 1992;30 Suppl 3:29-34.
 

104.Schuppan D. Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J Hepatol 1991;13 Suppl 3:17-25.
 

105.Schuppan D and Riecken EO. Molecules of the extracellular matrix: potential role of collagens and glycoproteins in intestinal adaptation. Digestion 1990;46 Suppl 2:2-11.
 

106.Stallmach A, Schuppan D, Riecken EO. The role of the extracellular matrix for cocarcinogenesis in the gastrointestinal tract. Dtsch Med Wschr 1990; 15:467-72.
 

107.Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Sem Liver Dis1990; 10:1-10.
 

108.Schuppan D, Hahn EG, Riecken EO. Changes in connective tissue metabolism in alcoholic liver fibrosis. Z Gastroenterol 1988;26 Suppl 3:28-38.